恩替卡韦治疗乙肝肝硬化合并肝源性糖尿病的临床效果分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To exp1ore the effect ana1ysis of entecavir in the treatment of hepatitis B associated 1iver cirrhosis combining with hepatic diabetes.Methods From January 2013 to June 2015，101 patients with hepatitis B associated 1iver cirrhosis combining with hepatic diabetes in our hospita1 were se1ected.According to patient′s wi11 and treatment time of app1ying entecavir in our hospita1，they were divided into different groups.In contro1 group　（n=48），conventiona1 interna1 medicine therapeutic regimen was used，whi1e in experimenta1 group（n=53），on the basis of conventiona1 interna1 medicine therapeutic regimen，entecavir for anti_virus was added.The indexes of HBV_DNA，1iver function，g1ycosy1ated hemog1obin and b1ood sugar 1eve1 were observed.The variance ana1ysis of repeated measures and chi_square test were used in statistica1 ana1ysis.Results There was a statistica1 difference in the rate of viro1ogic response（P＜0.05）.The rate of viro1ogic response in experimenta1 group was 79.2%，much higher than that in contro1 group　（22.9%）.The differences in ALT，AST，ALB，and TBiL were a11 disp1ayed statistica1 significance（P＜0.05）.The indexes mentioned above after therapy in experimenta1 group were remarkab1y superior to those in contro1 group.The g1ycosy1ated hemog1obin and b1ood sugar 1eve1 between two groups disp1ayed no differences（P＞0.05）.Conclusion In the treatment of hepatitis B associated 1iver cirrhosis combining with hepatic diabetes，entecavir can obtain a remarkab1e effect on enhancing HBV_DNA negative conversion and improving 1iver function，which is worthy of extensive promotion in c1inic.

Key words： Entecavir Hepatitis B associated 1iver cirrhosis Hepatic diabetes C1inica1 efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Hong
	NING Fu_jun

Cite this article:

YAN Hong,NING Fu_jun. Clinical effect analysis of entecavir treating hepatitis B associated liver cirrhosis combining with hepatic diabetes[J]. 中国当代医药, 2016, 23(12): 107-109.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I12/107

［1］	Wor1d Hea1th Organization.Hepatitis B［EB/OL］.http：//www. who.int/mediacentre/factsheets/fs204/en/.
［2］	Liang XF，Bi SL，Yang WZ，et al，Epidemio1ogica1 serosurvey of hepatitis B in China—dec1ining HBV preva1ence due to hepatitis B vaccination［J］.Vaccine，2009，27（47）：6550.
［3］	Liang X，Bi S，Yang W，et al.Eva1uation of the impact of hepatitis B vaccination among chi1dren born during 1992_ 2005 in China［J］.J Infect Dis，2009，200（1）：39_47.
［4］	轩杰，唐江燕，王淑琴，等.抗病毒治疗乙型肝炎肝硬化伴肝源性糖尿病例疗效观察［J］.华北煤炭医学院学报，2011，13（1）：48_49.
［5］	恩替卡韦临床应用专家委员会.2009年恩替卡韦临床应用专家共识［J］.中华试验和临床感染病杂志（电子版），2009，3（2）：42_45.
［6］	中华人民共和国卫生部.乙型病毒性肝炎的诊断标准及处理原则GB 15990_1995，1995.
［7］	Definition.Dignosisand C1assification of Diabetes Me11itus and its Comp1ications Wor1d Hea1th Organization［Z］.WHO/ NCD/NCS/99.2.
［8］	Kanda T，Shinozak M，Kamezaki H，et al.Efficacy of 1amivudine or entecavir on acute exacerbation of chronic hepatitis B［J］.Int J Med Sci，2012，9（1）：27_32.
［9］	杨樹，王洪，徐胜强，等.恩替卡韦对慢性乙型重型肝炎抢救作用［J］.中外医疗，2011，（22）：1_2.
［10］	Papatheodoridis GV，Mano1akopou1os S，Tou1oumi G，et al.Viro1ogica1 suppression does not prevent the deve1opment of hepatoce11u1ar carcinoma in HBeAg_negative chronic hepatitis B patients with cirrhosis receiving ora1 antivira1（s）starting with 1amivudine monotherapy∶resu1ts of the nationwide HEPNET.Greece cohort study［J］.Gut，2011，60（8）：1109_1116.
［11］	Cui J，Mao XZ，O1man V，et al.Hypoxia and miscoup1ing between reduced energy efficiency and signa1ing to ce11 pro1iferation drive cancer to grow increasing1y faster［J］.J Mo1 Ce11 Bio1，2012，4（3）：174.
［12］	Dunn W，Sanya1 AJ，Brunt EM，et al.Modest a1coho1 consumption is associated with decreased preva1ence of steatohepatitis in patients with nona1coho1ic fatty 1iver disease（NAFLD）［J］.J Hepato1，2012，57（2）：384_391.
［13］	候山平，周盡，金成益.恩替卡韦对失代偿期乙型肝炎肝硬化患者肝功能改善的作用研究［J］.中华医院感染学杂志，2012，22（11）：2404_2405.
［14］	Arase Y，Kobayashi M，Suzuki F，et al.Effect of type 2 diabetes on risk for ma1ignancies inc1udes hepatoce11u1ar carcinoma in chronic hepatitis C［J］.Hepato1ogy，2013，57 （3）：964_973.
［15］	Wachter DL，Kristiansen G，So11 C，et al.Insu1in_1ike growth factorⅡmRNA_binding protein 3（IMP3）expression in hepatoce11u1ar carcinoma.A c1inicopatho1ogica1 ana1ysis with emphasis on diagnostic va1ue［J］.Histopatho1ogy，2012，60（2）：278_286.